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Abstract
Background: Porcine circovirus 2 (PCV2) is a serious problem to the swine industry and can lead to significant
negative impacts on profitability of pork production. Syndrome associated with PCV2 is known as porcine
circovirus closely associated with post-weaning multisystemic wasting syndrome (PMWS). The capsid (Cap) protein
of PCV2 is a major candidate antigen for development of recombinant vaccine and serological diagnostic method.
The recombinant Cap protein has the ability to self-assemble into virus-like particles (VLPs) in vitro, it is particularly
opportunity to develop the PV2 VLPs vaccine in Escherichia coli,(E.coli ), because where the cost of the vaccine
must be weighed against the value of the vaccinated pig, when it was to extend use the VLPs vaccine of PCV2.
Results: In this report, a highly soluble Cap-tag protein expressed in E.coli was constructed with a p-SMK
expression vector with a fusion tag of small ubiquitin-like modifiers (SUMO). The recombinant Cap was purified
using Ni
2+ affinity resins, whereas the tag was used to remove the SUMO protease. Simultaneously, the whole
native Cap protein was able to self-assemble into VLPs in vitro when viewed under an electron microscope. The
Cap-like particles had a size and shape that resembled the authentic Cap. The result could also be applied in the
large-scale production of VLPs of PCV2 and could be used as a diagnostic antigen or a potential VLP vaccine
against PCV2 infection in pigs.
Conclusion: we have, for the first time, utilized the SUMO fusion motif to successfully express the entire authentic
Cap protein of PCV2 in E. coli. After the cleavage of the fusion motif, the nCap protein has the ability to self-
assemble into VLPs, which can be used as as a potential vaccine to protect pigs from PCV2-infection.
Background
Porcine circoviruses (PCVs), classified as a member of
the family Circoviridae, are small icosahedral non-envel-
oped viruses (size ~17 nm) containing a circular single-
stranded DNA molecule of about 1.7 kb. Two genotypes
of PCV have been described. PCV1 was first isolated
and characterized as a persistent contaminant of the
PK-15 cell line and is considered as a non-pathogenic
virus [1]. PCV2 is an etiologic agent that is associated
with post-weaning multisystemic wasting syndrome
(PMWS) [2,3]. PMWS is currently considered to be an
important infectious swine viral disease that has a ser-
ious economic impact on the pig farming industry.
Clinically, pigs affected with PMWS, frequently at 5 to
18 weeks of age, are characterized by pallor, progressive
weight loss, fever, difficulty in breathing, enlarged lymph
nodes, and, occasionally, diarrhea and jaundice. The
morbidity rate is usually low, but case fatality can be
more than 50% in affected herds [4].
The PCV2 genome contains two open reading frames
(ORFs). ORF1 encodes the replicase (Rep and Rep’) pro-
teins located on the viral plus strands, which initiates
viral replication. ORF2 encodes the major structural
capsid (Cap) protein, which is a sole structural protein
of the viral coat [5] and also the major immunogenic
protein that works together with the principal carrier of
type-specific epitopes [6]. The Cap protein is highly
immunogenic and reacts strongly with the serum of
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antigen for the design of new recombinant vaccines
against PCV2 infection and for the development of sero-
logic tests. There are several PCV2 vaccines currently on
the market. The CIRCOVAC® (Merial Com, lyon,
France), which is an inactivated PCV2 vaccine. The vac-
cine of Suvaxyn PCV2 One Dose (Fort Dodge Animal
Health, Fort Dodge, IA) was the first PCV2 vaccine
approved for commercial use in the United States by
the United States Department of Agticulture. This vac-
cine is a chimeric virus that was developed to have the
PCV2 capsid and the PCV1genome. Another available
two vaccines are subunit vaccine, Ingelvac® CIRCOFLX™
(Boehringer Ingelheim Vermdedica Inc, St. joseph, MO)
and Circumvent PCV (Intervet Inc, Millsboro, DE),
which are the capsid-based subunit vaccine expressed in
inactivated baculovirus. In recent years, two main
expression systems, including prokaryocytes and eukar-
yocytes, have been applied to express Cap protein as an
antigen for animal immunization against PCV2. The
prominent characteristic of the recombinant Cap protein
is its ability to independently self-assemble to form
virus-like particles (VLPs) in eukaryocytes, such as
insect-baculovirus and yeast expression systems [5,6].
However, few papers have reported on the production
of successful Cap protein VLPs in Escherichia coli
(E. coli) [7].
This is the first report on the production of Cap pro-
tein VLPs of PCV2 in E. coli. The small ubiquitin-like
modifier (SUMO) fusion expression system is used to
successfully express the whole native Cap (nCap) pro-
tein by making it highly soluble in E. coli.T h eS U M O
tag is subjected to cleavage with SUMO protease. Simul-
taneously, the whole nCap protein self-assembles into
VLPs in vitro.
Materials and methods
Construction of expression vectors with the fusion tag of
SUMO
The SUMO (Smt3) gene was amplified from Saccharo-
myces cerevisiae with primers Smt3F (5′-GCCATGG
(NcoI) GTCATCACCATCATCATCAC (6 × His) GGG-
TCGGACTCAGAAGTCAATCAA-3′)a n dS m t 3 R( 5 ′-G-
GATCC (BamHI) GAGACC (BsaI) TTAAGGTCTC
(BsaI) AACCTCCAATCTGTTCGCGGTG-3′). A NcoI
restriction site followed bya6×H i sc o d es e q u e n c ew a s
incorporated into the 5′ end of smt3. A 23-nucleotide
sequence containing BsaI on both positive and negative
strands and a BamHI restriction site were added to the 3′
end of smt3 gene. After double digestion with restriction
enzymes NcoI and BamHI, the amplified SUMO gene was
inserted into a pET-28a vector (Novagen) and digested
with the same enzymes. The resultant plasmid was desig-
nated as pSMK (Fig. 1).
Cloning the Cap gene and construction of a recombinant
expression vector
A pair of expression primers of ORF2 was designed with
the PCV2 sequences in the Genbank database (accession
numbers FJ948168 and FJ948167). The full-length Cap
gene (702 bp, the genotype is PCV2b) of PCV2 was ampli-
fied, using PCR from recombinant complete PCV2 gen-
ome plasmid previously stored in our laboratory, with the
following primers: the upstream primer (CGTGGT-
CTCCAGGTATGACGTATCCAAGGAGGCGT) con-
taining the BsaI site and the downstream primer
(TATCTCGAGTCAAGGGTTAAGTGGGGGGTCTTT)
containing the XhoI site. The PCR product was purified
and then digested with BsaI and XhoI (NEB), cloned into
p-SMK, and screened by transformants using restriction
enzyme analysis. The recombinant plasmid was designated
as p-SMK-Cap, which was transformed into the host,
BL21-codon-Plus (DE3)-RIL strain (Stratagene).
Expression and purification of recombinant Cap protein
An overnight culture of E. coli cells in Luria-Bertani (LB)
medium (plus 34 μg/ml chloramphenicol and 80 μg/ml
kanamycin) containing recombinant p-SMK-Cap plasmid
was diluted 1:50 in 0.2 L fresh LB medium and incubated
at 37°C until cells reached mid-log growth. The remainder
of the culture was induced by the addition of isopropyl-b-
thiogalactopyranoside (IPTG) to a final concentration of
0.1 mM and incubated further for 20 h at 20°C with shak-
ing at 180 rpm/min.
Cells were harvested by centrifugation at 5000 g for
15 min at 4°C. The cell pellet was resuspended in 50 ml
of 50 mM Tris-HCl buffer (1.0% Triton X-100, pH 8.0)
by stirring in an ice-cold water bath. The suspension
was disrupted on ice using ultrasonic cell crusher and
was centrifuged at 12000 g for 30 min at 4°C, and col-
lected using a 0.45 μm filter membrane, then equili-
brated with three columns of Tris-HCl buffer (20 mM
imidazole, 150 mM NaCl, pH 8.0) in a 70 ml column.
Figure 1 Scheme for the construction of the expression vector
p-SMK-Cap with SUMO motif.
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incubated for 30 min at 4°C. Superfluous recombinant
proteins were washed with a Tris-HCl buffer (30 mM
imidazole, pH 8.0) until the protein indicator cannot
turn blue in a Bradford reagent (v/v: 5% of 95% ethanol,
10% of 88% phosphoric acid, and 0.07 mg/ml Coomassie
brilliant blue G-250). Bound protein was eluted with a
Tris-HCl buffer (300 mM imidazole, 150 mM NaCl, pH
8.0) until the protein indicator cannot turn blue. The
eluted production was concentrated at 4°C. Then, 2 ml
SUMO protease buffer (50 mM Tris-HCl, 0.2% Igepal,
1 mM DTT, pH 8.0) was added into the solution. The
quantity of the purified Cap-tag protein was obtained by
the Bradford assay (Sigma-Aldrich, USA) using bovine
serum albumin as a standard. It was analyzed through
15% SDS-PAGE and stored at 4°C for further assay.
Cleavage of a SUMO tag from a Cap-tag protein to yield
authentic VLPs of Cap
A cleavage reaction assay was performed containing 1 ×
SUMO protease buffer, 40 μl SUMO protease (1 unit/μl,
Invitrogen), 40 μg fusion protein, and water added to a
total volume of 400 μl, and incubated for 5 h at 16°C.
The cleavage reaction was diluted with 2 ml binding
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0), mixed
with 200 μl resins, and bound for 50 min using gentle
agitation to keep the resin suspended. The supernatant
was transferred into an ultrafiltration tube and pro-
c e s s e da t4 ° Ca n d2 5 0 0gt oaf i n a lv o l u m eo f5 0 0μl.
The purified tagless nCap protein was identified through
15% SDS-PAGE. The VLP preparations were dialyzed
against phosphate-buffered saline (PBS, pH 7.4) to a
final volume of 30 μl and further confirmed by electron
microscopy.
Western blotting
Cap-tag and nCap, 30 μg respectively, which were trans-
ferred to an Immobilon-P transfer membrane (Millipore
Corporation, Bedford, MA, USA) in a transfer buffer
( 2 0m MT r i s - H C l ,1 9 0m Mg l y c i n e ,0 . 1 %S D S ,2 0 %
methanol, pH 8.3) using a Mini-protean® tetra cell (Bio-
Rad, USA) at 0.8 mA/cm
2 for 2 h. The membranes were
blocked with 5% skim milk powder in PBST (PBS con-
taining 0.05% Tween 20) and incubated with anti-His
monoclonal antibody (mouse, 1:5000), (Sigma, USA) fol-
lowed by a peroxidase-conjugated anti-mouse antibody.
The DAB reagent was used to develop the signal
Transmission electron microscopy
For TEM studies, 25 μgo ft h en C a pV L P sw e r e
adsorbed onto a copper grid (200 mesh) for 2.5 min at
room temperature. Then, the grids were dried gently
using filter paper. After staining with 3% phosphotungs-
tic acid (PTA) for 2.5 min, the excess liquid was
removed, and the samples were viewed using a TEM
(Hitachi, H-7100FA) at an acceleration voltage of 75 kV.
The nCap VLPs were observed by immunoelectron
microscopy. Anti-PCV2 serum (1:100) from 60 day-old
PCV2-vaccinated pig, was reacted with nCap VLPs at
4°C overnight. The products were centrifuged at 3500 g
for 10 min. The pellet was dissolved in PBS. The pre-
pared grid was stained by PTA and visualized by TEM.
Results
Expression, purification, and characterization of Cap
protein
T h ew h o l eC a pg e n ew a sa m p l i f i e db yP C Ro fP C V 2
genomic DNA and cloned into p-SMK expressed vector
with the SUMO tag (5’-6 × His-SUMO-Cap-3’)( F i g .1 ) .
The recombinant strains were induced at 20°C by IPTG.
The products were analyzed by SDS-PAGE. The Cap-
tag in E. coli is highly water-soluble. The supernatant of
cell lysis was purified on Ni
2+ affinity resins that have
the ability to specifically bind to His6-tag polypeptide.
T h ep u r i t yo ft h eC a p - t a gp r o tein is greater than 90%,
so it may be used as a template in the next protease
cleavage reaction (Fig. 2). The reaction of Cap-tag and
nCap may with anti-PCV2 pig sera and was observed by
Western blotting (Fig. 3).
Cleavage of His-Smt3 tag and assembly of Cap protein
VLPs
After the cleavage of the His-Smt3 tag with SUMO pro-
tease from the Cap-tag, the mixture was again passed
through Ni
2+ affinity resins. The cleaved His-Smt3 tag
and the SUMO protease bind to the column, whereas
nCap protein (about 26kDa) can be recovered in the
flow-through and observed by SDS-PAGE.
Figure 2 SDS-PAGE analysis of the Cap-tag protein expression
in E. coli. Lane M, molecular weight marker; lane 1, bacterial lysates
from cells without IPTG; lane 2, bacterial lysates from IPTG-induced
cells in E. coli; lane 3, pellet from bacterial lysates; lane 4,
supernatant of bacterial lysates; lane 5, purified recombinant Cap-
tag protein.
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TEM and immunoelectron microscopy of the nCap pro-
tein show that it can assemble into Cap-like particles
with diameter ranging from 15 to 20 nm (Fig. 4A and
4B), and an anti-PCV2 antibody that reacts with Cap
VLPs antigen to produce complexs(Fig. 4C). The results
suggest that the Cap protein expressed from E. coli
assembles into VLPs.
Discussion
It is usually difficult to express the whole Cap protein in
E. coli possibly because of the specific amino acid at the
N terminus of a nuclear localization signal (NLS) [8]. In
whole Cap protein expression process, additional fusion
protein partners, such as glutathione S-transferase or
maltose binding protein, are able to achieve expression in
minute amounts [9,10]. Only the deletion of the whole
NLS domain may allow for the expression of a large
amount of the Cap protein. However, the NLS plays an
important role forming the self assembly of Cap-like par-
ticles and retains the antigenic function of the protein
[11]. The N terminus of the Cap protein of the NLS
domain is rich in arginine residues, which is a low-usage
codon in E. coli. Thus, by using codon optimization to
achieve Cap protein [12] and to overcome the difficulty
of expressing an authentic Cap protein and proceeding to
form VLPs in vitro, we recently constructed a SUMO
fusion protein expression system to produce the high-
level water-soluble Cap protein of PCV2 in E. coli.
Each prokaryocyte and eukaryocyte expression system
has advantages and limitations. In contrast, E. coli has
been a successful host for high expression levels of
many heterologous proteins because of its relative sim-
plicity, low cost, efficient generation time, and fast high-
density cultivation. Nevertheless, challenges need to be
overcome, such as proteolytic degradation of the target
protein, misfolding, formation of inclusion bodies, and
successful expression of soluble heterologous proteins.
Some fusion motifs or partners are frequently employed
to resolve the problems during the construction of
expression vectors in E. coli [13-15].
The SUMO fusion expression system offers advan-
tages over other fusion technologies, including improved
soluble expression, proper folding, protection from
degradation, and simplified purification and detection
[16]. To differentiate from other proteases that recog-
nize a peptide sequence and after cleaving, the fusion
tag can generate extraneous amino acids at the N termi-
nus of the target protein [17]. The SUMO protease
recognizes the tertiary structure of the SUMO tag, is
accurate and efficient for the generation of native
N-terminal amino acids, and does not result in extra-
n e o u sr e s i d u e sa tt h eNt e r m i n u so ft h et a r g e tp r o t e i n
in recombinant proteins [16]. These demonstrate its
authentic traits.
VLPs mimic the structure of authentic virus particles
and present viral antigens in a more authentic confor-
mation and biological function. Therefore, they are
easily recognized by the immune system and able to sti-
mulate both B-cell and T-cell immune responses
[18-20]. In particular, many VLPs are non-infectious
because, although they completely lack the viral DNA or
RNA genome, they are safer than attenuated or chemi-
cally inactivated live viruses. This striking feature of
VLPs will likely contribute to the effectiveness of its use
in vaccination as a strategy for controlling diseases
[21-24].
Figure 3 Western blotting analysis of different Cap proteins
with anti-PCV2 pig sera. M, molecular weigh standard; Lane 1,
uninduced recombinant E. coli; lanes 2 and 3, nCap protein
cleavage of SUMO + 6 × His tag; lane 4, recombinant fusion Cap
protein with SUMO + 6 × His tag.
Figure 4 TEM images of recombinant Cap protein VPLs of PCV2. The recombinant Cap-tag protein (A) and Cap protein VPLs after cleavage
of the SUMO tag (B); immunoelectron microscopy image of the Cap protein VPLs (C). Scale bar is 50 nm.
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protein of PCV2 is successfully expressed in E. coli as
highly soluble substances. The study also shows that the
fusion tag is subjected to cleavage with the SUMO pro-
tease. Simultaneously, the whole Cap protein is able to
self-assemble into VLPs in vitro. TEM confirmed that
its shape and size are similar to Cap isolated from the
cell culture. The antigenic property of Cap protein VLPs
was confirmed by Western blotting and immunoelectron
microscopy.
Conclusions
In summary, we have, for the first time, utilized the
SUMO fusion motif to successfully express the entire
authentic Cap protein of PCV2 in E. coli. After the clea-
vage of the fusion motif, the nCap protein has the ability
to self-assemble into VLPs, which can be used as a
potential VLPs vaccine to p r o t e c tp i g sf r o mP C V 2 -
infection.
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